Clinical Trials Logo

Clinical Trial Summary

Chronic atrophic gastritis (CAG) is a common and frequently-occurring disease, characterized by atrophy of gastric mucosal epithelium and glands, thinning of the mucosa, thickening of the submucosal muscle layer, intestinal metaplasia, and atypical hyperplasia. The course of the disease is protracted and often recurrent, which seriously affects the work and physical and mental health of the patient. Moreover, epidemiological studies have shown that the risk of gastric cancer in patients with chronic multifocal atrophic gastritis is significantly higher than that of the general population. Because CAG intestinal metaplasia and dysplasia can easily develop into gastric cancer, the World Health Organization (WHO) listed CAG's gastric mucosal atrophy, intestinal metaplasia and dysplasia as precancerous lesions of gastric cancer in 1978. Therefore, reversing and disappearing the precancerous state of gastric cancer is an effective measure to prevent the occurrence of gastric cancer. The cause of CAG is complicated. Modern medicine believes that CAG is closely related to biological factors, physical and chemical factors, immune factors, and genetic factors. At present, there is no specific treatment, but symptomatic treatment is the main treatment. The disease belongs to the categories of "stomach pain" and "suffocation" in traditional Chinese medicine. In many years of surveys and studies in Mainland China, it is found that Dendrobii granules have a good effect on chronic atrophic gastritis. It is planned to explore the possibility, effectiveness and safety of Dendrobii granules in the treatment of chronic atrophic gastritis through clinical trials. 20 subjects will be randomized into the treatment group and placebo group with 18 weeks of treatment.


Clinical Trial Description

Chronic atrophic gastritis, (CAG) is a common and frequently-occurring disease, characterized by atrophy of gastric mucosal epithelium and glands, thinning of the mucosa, thickening of the submucosal muscle layer, intestinal metaplasia, and atypical hyperplasia. The course of the disease is protracted and often recurrent, which seriously affects the work and physical and mental health of the patient. Moreover, epidemiological studies have shown that the risk of gastric cancer in patients with chronic multifocal atrophic gastritis is significantly higher than that of the general population. Because CAG intestinal metaplasia and dysplasia can easily develop into gastric cancer, the World Health Organization (WHO) listed CAG's gastric mucosal atrophy, intestinal metaplasia and dysplasia as precancerous lesions of gastric cancer in 1978. Therefore, reversing and disappearing the precancerous state of gastric cancer is an effective measure to prevent the occurrence of gastric cancer. The study of CAG gastric mucosal atrophy and intestinal metaplasia reversal drugs not only has important academic significance, but also has good social and economic benefits, and has a broad market prospect. The cause of CAG is complicated. Modern medicine believes that CAG is closely related to biological factors, physical and chemical factors, immune factors, and genetic factors. At present, there is no specific treatment, but symptomatic treatment is the main treatment. The disease belongs to the categories of "stomach pain" and "suffocation" in traditional Chinese medicine. The Chinese Medicine practitioners in the past have advocated that the main treatment is to nourish the stomach. For more than two thousand years, a better understanding of Dendrobii used for "thick intestines and stomach", "calm the stomach", "replenish five internal organs and fatigue", and "light body and prolong life". There are many varieties of Dendrobii, especially Dendrobii officinale is the top grade. Dendrobii candidum is combined with American ginseng to nourish qi and nourish yin, nourish the stomach and promote fluid, nourish but not greasy, clear but not hurt the stomach. This study used the Granules Dendrobii produced by Zhejiang Tianhuang Medical Plant Pharmaceutical Co., Ltd. (Hong Kong proprietary Chinese medicine registration number: HKC-16115). Granules Dendrobii has completed many pharmacodynamic and toxicological studies. In the many years of market investigation and research in Mainland China, it is found that Granules Dendrobii (Hong Kong Chinese Patent Medicine Registration Number: HKC-16115) has a good effect on chronic atrophic gastritis. Granules Dendrobii is suitable for the long-term conditioning and rehabilitation of spleen and stomach diseases that are weakened by spleen and stomach, or due to deficiency and solidification, resulting in spleen and stomach diseases mixed with deficiency and solid. Granules] with Dendrobium candidum as the main ingredient in the treatment of chronic atrophic gastritis has the traditional theoretical basis of Chinese medicine. Now plan to explore the possibility, effectiveness and safety of Granules Dendrobii in the treatment of chronic atrophic gastritis (qi and yin deficiency) through clinical trials. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05209633
Study type Interventional
Source Chinese University of Hong Kong
Contact Cho Wing Lo
Phone 35053476
Email [email protected]
Status Not yet recruiting
Phase Phase 2
Start date June 2022
Completion date August 2023

See also
  Status Clinical Trial Phase
Completed NCT02351154 - Grading Atrophic Gastritis by Confocal Laser Endomicroscopy Probe (p-CLE) N/A
Completed NCT02724280 - Linked Color Imaging to Differentiate H. Pylori Associated Gastritis and Gastric Atrophy N/A
Completed NCT02597517 - New Technology to Differentiate Normal Gastric Mucosa From Helicobacter Pylori Associated Gastritis and Gastric Atrophy N/A
Recruiting NCT04022109 - Screening of Gastric Cancer Via Breath Volatile Organic Compounds by Hybrid Sensing Approach
Recruiting NCT05053945 - Helicobacter Pylori, Atrophic Gastritis and Intestinal Metaplasia Registry and Prospective Study
Recruiting NCT02047994 - Multicentric Randomized Study of H. Pylori Eradication and Pepsinogen Testing for Prevention of Gastric Cancer Mortality Phase 4
Completed NCT01896310 - New Classification of Stomach Using Probe-based Confocal Laser Endomicroscopy N/A
Recruiting NCT04191551 - The GAstric Precancerous Conditions Study
Enrolling by invitation NCT03228095 - Volatiles in Breath and Headspace Analysis - Diagnostic Markers
Recruiting NCT02833363 - Difference of Gastric Microbiota in the Process of Correa's Model. Phase 4
Enrolling by invitation NCT05021029 - A Study of Pre-Malignant Gastric Conditions
Recruiting NCT04085211 - Image-Enhanced Endoscopy in the Gastrointestinal Tract
Completed NCT02332213 - Volatile Markers in Digestive Cancer
Recruiting NCT04613570 - SUrveillance of PREMalignant Stomach - Individualized Endoscopic Follow-up N/A
Not yet recruiting NCT04251403 - Novel Approach to Surveillance of Gastric Lesions Early Phase 1
Recruiting NCT02691637 - Effect of H. Pylori Eradication on the Reversibility of Atrophic Gastritis and Intestinal Metaplasia in Korean Patients
Recruiting NCT03380052 - OLGA and OLGIM Stage System for Gastric Cancer
Recruiting NCT04184960 - AG & IM in CA Stomach Protocol
Recruiting NCT02184910 - Usefulness of Serum Pepsinogen and Gastrin as the Predictive Biomarker of Atrophic Gastritis, Intestinal Metaplasia and Gastric Cancer in Korea
Recruiting NCT04840056 - Prediction of Gastric Cancer in Intestinal Metaplasia and Atrophic Gastritis